Treatment Options and How Doctors Choose Among Them
At a Glance
Treatment for fungal infections in people with CARD9 deficiency often lasts months because the immune system cannot reliably clear certain fungi. Doctors tailor drugs to the fungus and infection site, monitor levels and side effects, and may use surgery or long-term suppression to prevent relapse.
Treating a fungal infection in a person with CARD9 deficiency is very different from treating a typical infection. Because your immune system cannot help clear the fungus, the medication must do all the heavy lifting [1]. This usually requires much longer treatment courses and a more aggressive approach than standard medical care [2].
Systemic Antifungal Therapy
Treatment is typically broken into two phases: induction (the initial, aggressive attack) and consolidation/maintenance (keeping the fungus from coming back). The regimen is completely individualized based on the organism and site of infection.
- Induction Phase: For serious infections like CNS candidiasis (brain/spinal cord), treatment often starts with liposomal amphotericin B [2]. This is a powerful “broad-spectrum” antifungal usually given through an IV. It may be paired with another drug called flucytosine to help it penetrate the brain more effectively [2][3]. Conversely, invasive mold infections (like Aspergillus or phaeohyphomycosis) are commonly managed with mold-active azoles rather than automatically using an amphotericin-based regimen.
- Maintenance Phase: Once the infection is under control, you may be switched to oral medications like fluconazole, voriconazole, or posaconazole [4][5].
- Extended Duration: Treatment in CARD9 deficiency is measured in months, not weeks. For example, clearing Candida from the central nervous system has taken 16 months or more of continuous therapy in specific reported cases [6]. Duration is based on clinical, radiologic, microbiologic, and toxicity considerations under specialist supervision.
The Importance of Monitoring
Because these drugs must be taken for a long time and at high doses, therapeutic drug monitoring (TDM) is essential for certain medications (like some azoles or flucytosine) [7].
- Checking Drug Levels: Your care team will regularly test your blood serum (and rarely, in specific circumstances, your spinal fluid) to ensure the drug level is high enough to kill the fungus but low enough to avoid damaging your body [5][8].
- Medication Safety: Different drugs require different organ safety checks. Amphotericin requires close monitoring for kidney injury and electrolyte loss. Flucytosine requires bone marrow and liver toxicity checks. Azole drugs carry risks of liver toxicity, heart rhythm changes (QT prolongation), and major interactions with over-the-counter herbs and other prescriptions. Speak to your doctor about which symptoms (like jaundice or palpitations) require an urgent call, and discuss pregnancy or contraception considerations if you are on long-term azole therapy.
- Susceptibility Testing: If an infection isn’t getting better, doctors will perform “susceptibility testing” in a lab. They grow your specific fungus and test it against different drugs to see which one works best. This is especially important for rare molds (phaeohyphomycosis), which can be naturally resistant to some common antifungals [9][10].
The Role of Surgery
Medication sometimes cannot reach the center of a large fungal mass or an infected bone. In these cases, surgical intervention is used alongside antifungals [11].
- Source Control: This includes draining abscesses, removing infected lymph nodes, or even removing infected devices like shunts or catheters [12][2].
- Bone and Tissue Removal: In severe cases of deep dermatophytosis (deep skin and bone infection), surgery may be necessary to remove “dead” or heavily infected tissue so the remaining healthy tissue has a chance to heal [13][14].
Preventing Relapse
The biggest challenge in CARD9 deficiency is that the fungus often returns as soon as treatment stops. One review of a selected series of cases found that 44 out of 45 patients who initially got better later experienced a relapse [1]. This striking number highlights the risk, though it comes from a cohort of severe cases and may not apply to every patient.
- Suppressive Prophylaxis: Because the risk of the infection returning is so high, many specialists consider long-term suppressive therapy [1]. This means taking a daily antifungal pill indefinitely to keep the fungus from causing a new, life-threatening infection [15][16]. However, lifelong secondary prophylaxis is an individualized decision with substantial toxicity, interaction, adherence, and cost implications; it is not automatically required for everyone.
- Never Stop Early: It is critical never to stop or skip doses of your antifungal medication without talking to your specialist. Even a short break can allow a stubborn fungus to begin growing again [17].
Common questions in this guide
How is a serious fungal infection treated when someone has CARD9 deficiency?
How long will antifungal treatment last with CARD9 deficiency?
Why do I need drug levels and regular safety tests?
When might surgery be added to antifungal treatment?
Will I need antifungal medicine for life after the infection clears?
What happens if the infection does not improve with the first antifungal?
Is it safe to stop antifungal treatment when I feel better?
Get notified when new evidence is published on Predisposition to invasive fungal disease due to CARD9 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Inherited CARD9 Deficiency: Invasive Disease Caused by Ascomycete Fungi in Previously Healthy Children and Adults.
Corvilain E, Casanova JL, Puel A
Journal of clinical immunology 2018; (38(6)):656-693 doi:10.1007/s10875-018-0539-2.
PMID: 30136218 - 2
[Candidiasis].
Kageyama Y, Katakami T
Brain and nerve = Shinkei kenkyu no shinpo 2026; (78(5)):585-588 doi:10.11477/mf.188160960780050585.
PMID: 42156051 - 3
Candida Meningitis After Transsphenoidal Surgery: A Single-Institution Case Series and Literature Review.
Bridges KJ, Li R, Fleseriu M, Cetas JS
World neurosurgery 2017; (108()):41-49 doi:10.1016/j.wneu.2017.08.115.
PMID: 28847554 - 4
A 7-Year-Old Child With Headaches and Prolonged Fever Associated With Oral and Nail Lesions.
Martin S, Balligand E, Peeters J, et al.
Open forum infectious diseases 2019; (6(11)):ofz229 doi:10.1093/ofid/ofz229.
PMID: 31700940 - 5
Invasive cerebral phaeohyphomycosis in a Chinese boy with CARD9 deficiency and showing unique radiological features, managed with surgical excision and antifungal treatment.
Lai SHY, Duque JSR, Chung BH, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021; (107()):59-61 doi:10.1016/j.ijid.2021.04.052.
PMID: 33872781 - 6
Chronic Candida albicans Meningitis in a 4-Year-Old Girl with a Homozygous Mutation in the CARD9 Gene (Q295X).
Herbst M, Gazendam R, Reimnitz D, et al.
The Pediatric infectious disease journal 2015; (34(9)):999-1002 doi:10.1097/INF.0000000000000736.
PMID: 25933095 - 7
Deep and disseminated dermatophytosis in immunocompromised populations-A systematic review.
Gupta AK, Wang T, Susmita , et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(10)):1648-1661 doi:10.1111/jdv.70115.
PMID: 41104791 - 8
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE, Hope WW
The Journal of antimicrobial chemotherapy 2017; (72(suppl_1)):i12-i18 doi:10.1093/jac/dkx029.
PMID: 28355463 - 9
Antifungal Susceptibility of Melanized Fungi Isolated from CARD9 Deficient Patients: Implications for Treatment of Refractory Infections.
Ji Y, Li Y, Wu W, et al.
Mycopathologia 2025; (190(2)):29 doi:10.1007/s11046-025-00936-8.
PMID: 40021530 - 10
The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
Zhou PY, Lim TP, Tang SLS, et al.
Journal of global antimicrobial resistance 2020; (21()):427-433 doi:10.1016/j.jgar.2019.12.004.
PMID: 31846723 - 11
Phaeohyphomycosis caused by Phialophora americana with CARD9 mutation and 20-year literature review in China.
Huang C, Zhang Y, Song Y, et al.
Mycoses 2019; (62(10)):908-919 doi:10.1111/myc.12962.
PMID: 31271673 - 12
Surgical management of deep dermatophytosis in a patient with CARD9 deficiency.
El Maati M, Berjaou Z, Hammouch Z, et al.
Journal of surgical case reports 2023; (2023(7)):rjad388 doi:10.1093/jscr/rjad388.
PMID: 37426045 - 13
Deep dermatophytosis caused by Trichophyton rubrum in an elderly patient with CARD9 deficiency: A case report and literature review.
Ansai O, Hayashi R, Nakamura A, et al.
The Journal of dermatology 2024; (51(2)):294-300 doi:10.1111/1346-8138.16995.
PMID: 37804063 - 14
Therapeutic management of subcutaneous phaeohyphomycosis and chromoblastomycosis in kidney transplant recipients: a retrospective study of 82 cases in a single center.
Lima ACC, Santos DWCL, Hirata SH, et al.
International journal of dermatology 2022; (61(3)):346-351 doi:10.1111/ijd.15948.
PMID: 34633082 - 15
Endogenous Candida endophthalmitis and osteomyelitis associated with CARD9 deficiency.
Jones N, Garcez T, Newman W, Denning D
BMJ case reports 2016; (2016()).
PMID: 26941346 - 16
CARD9 deficiency with allergic bronchopulmonary aspergillosis (ABPA)-like presentation: a case report.
Fallahi M, Mahdaviani SA, Shafiei M, et al.
Oxford medical case reports 2023; (2023(10)):omad103 doi:10.1093/omcr/omad103.
PMID: 37881270 - 17
[CARD9 Mutation in a Patient with Candida albicans Meningoencephalitis; A Case Report].
Kuruoğlu T, Çelik M, Çelmeli F, Tanyel E
Mikrobiyoloji bulteni 2021; (55(4)):656-664 doi:10.5578/mb.20219717.
PMID: 34666665
This page explains treatment considerations for fungal infections in people with CARD9 deficiency for informational purposes only and does not replace medical advice. Antifungal choice, monitoring, surgery, and treatment duration must be individualized with an infectious-disease specialist.